Valuation: Protalix BioTherapeutics, Inc.

Market Cap 193M 0 170M 158M 145M 273M 18.54B 276M 1.88B 735M 9.16B 726M 710M 31.65B P/E 2026 *
12.3x
P/E 2027 * 48x
Enterprise Value 193M 0 170M 158M 145M 273M 18.54B 276M 1.88B 735M 9.16B 726M 710M 31.65B EV / Sales 2026 *
2.47x
EV / Sales 2027 * 2.86x
Free-Float
96.12%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 59 30/06/2019
Director of Finance/CFO 57 24/08/2025
Chief Tech/Sci/R&D Officer - 01/06/2024
Director TitleAgeSince
Director/Board Member 73 01/07/2008
Director/Board Member 82 01/11/2014
Director/Board Member 59 30/06/2019
Change 5-day change 1-year change 3-year change Capi.($)
-.--%+3.29% - - 193M
+2.14%+3.88%+51.10%+166.32% 1,068B
+2.55%+9.25%+64.71%+56.91% 641B
+3.10%+3.62%+40.76%+75.91% 454B
+1.71%+9.92%+40.79%+36.19% 351B
+1.70%+4.06%+39.96%+44.75% 299B
+0.99%+4.27%+20.72%+17.79% 266B
+1.86%+2.61%-26.30%-37.07% 220B
+4.64%+7.53%+30.71%+66.62% 203B
+2.63%+3.35%+19.13%+75.19% 162B
Average +2.23%+2.76%+31.29%+55.85% 407.04B
Weighted average by Cap. +2.42%+2.85%+40.91%+81.05%

Financials

2026 *2027 *
Net sales 78.3M 0 68.83M 64.07M 58.84M 110M 7.51B 112M 762M 297M 3.71B 294M 288M 12.81B 67.56M 0 59.4M 55.29M 50.78M 95.35M 6.48B 96.6M 657M 257M 3.2B 254M 248M 11.06B
Net income 15.72M 0 13.82M 12.87M 11.82M 22.19M 1.51B 22.48M 153M 59.73M 745M 59.02M 57.75M 2.57B 4.07M 0 3.58M 3.33M 3.06M 5.75M 391M 5.82M 39.62M 15.48M 193M 15.29M 14.96M 667M
Net Debt - -
Logo Protalix BioTherapeutics, Inc.
Protalix BioTherapeutics, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx. In addition, the Company is developing PEGylated uricase, or PRX-115, for the treatment of uncontrolled gout, Long Acting (LA) DNase I, or PRX-119, for the treatment of NETs-related diseases, and other technologies and preclinical assets. Its ProCellEx platform is being used to manufacture both of its approved and marketed products as well as PRX-115 and PRX-119. PRX-115, a plant cell-expressed recombinant PEGylated Uricase (urate oxidase) - a chemically modified enzyme to treat uncontrolled gout. PRX-119 is a plant cell-expressed PEGylated recombinant human DNase I product candidate. Its product includes Elelyso and Elfabrio. Elelyso is an enzyme replacement therapy (ERT) for the treatment of patients with Gaucher disease.
Employees
-
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
2.400USD
Average target price
11.00USD
Spread / Average Target
+358.33%

Quarterly revenue - Rate of surprise